Experienced in Ewing Sarcoma

Dr. Thierry M. Jahan

Oncology | Hematology
1600 Divisadero St, 
San Francisco, CA 
 (535.8 mi)
Experienced in Ewing Sarcoma
1600 Divisadero St, 
San Francisco, CA 
 (535.8 mi)
OverviewInsuranceLocationsClinical Research

Overview

Thierry Jahan is an Oncologist and a Hematologist in San Francisco, California. Dr. Jahan and is rated as an Experienced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Mesothelioma, Epithelioid Sarcoma, Adult Soft Tissue Sarcoma, and Lung Cancer.

His clinical research consists of co-authoring 44 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

1600 Divisadero St, San Francisco, CA 94115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2025
Intervention Type: Drug, Other
Study Drug: Adjuvant Chemotherapy
Study Phase: Not Applicable
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Enrollment Status: Completed
Publish Date: March 16, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function
A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function
Enrollment Status: Completed
Publish Date: April 09, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients With Stage IV (Including Pleural Effusion) Non Squamous NSCLC Who Have Failed Two Lines of Anti-Cancer Therapy
A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients With Stage IV (Including Pleural Effusion) Non Squamous NSCLC Who Have Failed Two Lines of Anti-Cancer Therapy
Enrollment Status: Completed
Publish Date: December 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 With Pembrolizumab in Adults With Previously-Treated Malignant Pleural Mesothelioma
A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 With Pembrolizumab in Adults With Previously-Treated Malignant Pleural Mesothelioma
Enrollment Status: Terminated
Publish Date: April 04, 2019
Intervention Type: Biological
Study Phase: Phase 2
View 6 Less Clinical Trials

44 Total Publications

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: October 22, 2020
Similar Doctors
Distinguished in Ewing Sarcoma
Dr. Kristen N. Ganjoo
Oncology
Distinguished in Ewing Sarcoma
Dr. Kristen N. Ganjoo
Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (28.3 mi)
650-723-4000
Languages Spoken:
English
Offers Telehealth

Kristen Ganjoo is an Oncologist in Stanford, California. Dr. Ganjoo and is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, Gastrointestinal Stromal Tumor, and Pancreaticoduodenectomy.

Advanced in Ewing Sarcoma
Dr. Varun Monga
Hematology Oncology | Oncology
Advanced in Ewing Sarcoma
Dr. Varun Monga
Hematology Oncology | Oncology

Ucsf Medical Group Business Services

505 Parnassus Ave, 
San Francisco, CA 
 (1.8 mi)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Varun Monga is a Hematologist Oncology specialist and an Oncologist in San Francisco, California. Dr. Monga and is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Astrocytoma, Glioblastoma, Glioma, and Splenectomy.

Advanced in Ewing Sarcoma
Dr. Ross Okimoto
Hematology | Oncology | Hematology Oncology
Advanced in Ewing Sarcoma
Dr. Ross Okimoto
Hematology | Oncology | Hematology Oncology

Ucsf Medical Group Business Services

400 Parnassus Ave, 
San Francisco, CA 
 (1.7 mi)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ross Okimoto is a Hematologist and an Oncologist in San Francisco, California. Dr. Okimoto and is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Undifferentiated Pleomorphic Sarcoma, Adult Soft Tissue Sarcoma, Bone Tumor, and Liposarcoma.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile